Skip to main content

Clinical evaluation of endotoxin hemoadsorption therapy (PMX-DHP) for hypercytokinemia caused by septic multiple organ failure

The limitations of endotoxin hemoadsorption therapy (PMX-DHP) and the optimal time to start PMX-DHP were examined in patients with septic multiple organ failure with hypercytokinemia (IL-6 > 1000 pg/ml). This study included 66 patients with infectious systemic inflammatory response syndrome in whom IL-6 > 1000 pg/ml before PMX-DHP therapy. These subjects were separated into two groups, those who survived for more than 28 days after the start of PMX-DHP therapy (S group; 38 patients) and those who did not survive (N-S group; 28 patients). Severity of symptoms and background factors, hemodynamic parameters, PaO2/FiO2, endotoxin, cytokines (TNF-α, IL-6, IL-1ra), and vascular endothelial cell function-related markers (ICAM-1, ELAM-1, PAI-1) were examined before and after PMX-DHP. Statistical analyses were performed by chi-squared test for background factors, with Wilcoxon's signed rank test for comparison within a group, and Mann–Whitney's U test for comparison between groups. This study was approved by the IRB of Tokyo Medical University.

Results

The APACHE-II score was 22.9 ± 6.3 and 30.7 ± 8.9, and the SOFA score was 9.7 ± 3.6 and 12.6 ± 3.4 in the S and N-S groups, respectively, showing significantly higher scores in the N-S group. The number of days that had lapsed from the onset of shock to PMX-DHP initiation was 0.8 ± 0.8 days in the S group while it was longer (1.8 ± 1.2 days) in the N-S group. After PMX-DHP for 2 hours, the endotoxin level decreased from 26.1 ± 20.3 to 20.3 ± 24.5 pg/ml with statistical significance (P < 0.05) in the S group. In the N-S group, it tended to decrease from 23.6 ± 20.3 to 10.9 ± 17.2 pg/ml.

Conclusion

These results suggest that PMX-DHP could save more lives in patients with septic multiple organ failure with IL-6> 1000 pg/ml when applied early after the onset of shock.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ikeda, T., Ikeda, K., Nagura, M. et al. Clinical evaluation of endotoxin hemoadsorption therapy (PMX-DHP) for hypercytokinemia caused by septic multiple organ failure. Crit Care 8, P148 (2004). https://doi.org/10.1186/cc2615

Download citation

Keywords

  • Emergency Medicine
  • Clinical Evaluation
  • Rank Test
  • Signed Rank Test
  • Optimal Time